Skip to content

Ardent Health

US · ARDT #2983 by market cap Listed 2024
10.88 +0.20 +1.87%
Live - 5344 symbols - heartbeat 313s ago · 2026-10-08 04:00
Pre-market 10.81 -0.61%
After-hours 10.88 0.00%
Overnight 10.75 -1.19%
Market cap
1.53B
P/B
1.14
EPS
0.96
Reader sentiment Are you bullish or bearish on ARDT?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
5.19 fair value ≈ 14.12 23.05
  • Implied fair-value range of 5.19-23.05, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -23.0% below the average-multiple fair value of 14.12.

Valuation each multiple against its own 5-year range

P/B ratio 1.12 Cheap vs history 32nd percentile
5-year average 1.72 · #10 of 40 in Medical Care Facilities
P/E ratio 19.42 Expensive vs history 67th percentile
5-year average 14.71 · forward 10.01 · #15 of 30 in Medical Care Facilities
P/S ratio 0.24 In line with history 34th percentile
5-year average 0.30 · forward 0.23 · #9 of 50 in Medical Care Facilities

Vs. peers Medical Care Facilities

Company Market cap P/E (TTM) P/B Div yield
Ardent Health (ARDT) 1.53B 19.78 1.14 0.00%
HCA Healthcare (HCA) 95.08B 14.73 -14.32 0.68%
Tenet Healthcare (THC) 20.92B 10.04 4.49 0.00%
Encompass Health (EHC) 12.08B 19.95 4.65 0.62%
DaVita (DVA) 11.28B 14.57 -14.74 0.00%
Fresenius Medical Care (FMS) 11.01B 11.14 0.78 4.13%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value15.05 Economic moatNone UncertaintyHigh

Trading 38.3% below Morningstar's fair value estimate.

Fair value

Ardent Health Inc is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 29% discount to our quantitative fair value estimate of $15.05 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 92.0%, which falls in the top 40% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 7.7%, for example, lies in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 04:00:02 · For reference only, not investment advice and not tailored to your situation.